BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

11.53B

Market cap11.53B

Price-Earnings ratio

33.74

Price-Earnings ratio33.74

Dividend yield

—

Dividend yield—

Average volume

1.90M

Average volume1.90M

High today

$60.41

High today$60.41

Low today

$59.25

Low today$59.25

Open price

$60.18

Open price$60.18

Volume

195.22K

Volume195.22K

52 Week high

$73.18

52 Week high$73.18

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

With a market cap of 11.53B, BioMarin(BMRN) trades at $59.97. The stock has a price-to-earnings ratio of 33.74.

On 2026-03-11, BioMarin(BMRN) stock moved within a range of $59.25 to $60.41. With shares now at $59.97, the stock is trading +1.2% above its intraday low and -0.7% below the session's peak.

Trading volume for BioMarin(BMRN) stock has reached 195.22K, versus its average volume of 1.9M.

Over the past 52 weeks, BioMarin(BMRN) stock has traded between a high of $73.18 and a low of $50.76.

BMRN News

TipRanks 3h

BioMarin: Strategic Amicus Acquisition Supports Buy Rating Despite Voxzogo Assumption Reset

Analyst Jason Gerberry from Bank of America Securities reiterated a Buy rating on BioMarin Pharmaceutical and decreased the price target to $85.00 from $97.00....

TipRanks 3h

BioMarin price target lowered to $85 from $97 at BofA

BofA lowered the firm’s price target on BioMarin (BMRN) to $85 from $97 and keeps a Buy rating on the shares. The firm, which updated its outlook for the pro-fo...

Simply Wall St 13h

PALYNZIQ Pediatric Label Expansion Under REMS Might Change The Case For Investing In BioMarin

BioMarin Pharmaceutical Inc. recently received FDA approval for a supplemental Biologics License Application expanding PALYNZIQ (pegvaliase-pqpz) use to pediatr...

Analyst ratings

81%

of 26 ratings

Buy

80.8%

Hold

19.2%

Sell

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.